1. Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease—results of the Immune Metabolic Associations in Psoriatic Arthritis study
- Author
-
Naveed Sattar, Iain B. McInnes, John Harvie, Aleksandra Radjenovic, Rosemary Brown, Katriona Brooksbank, Paul Welsh, Caron Paterson, Xuan Gao, Stefan Siebert, Lyn D. Ferguson, Dominic Rimmer, Susanne Cathcart, and Gary Semple
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adipose tissue ,Gastroenterology ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Psoriatic arthritis ,chemistry.chemical_compound ,0302 clinical medicine ,Rheumatology ,Weight loss ,Psoriasis ,Internal medicine ,Adipocyte ,Weight Loss ,medicine ,Body Fat Distribution ,Humans ,Glucose homeostasis ,Pharmacology (medical) ,Prospective Studies ,030203 arthritis & rheumatology ,business.industry ,Arthritis, Psoriatic ,Weight change ,Cardiometabolic Risk Factors ,Middle Aged ,medicine.disease ,Thalidomide ,chemistry ,Female ,Phosphodiesterase 4 Inhibitors ,Apremilast ,medicine.symptom ,business ,medicine.drug - Abstract
Objectives Studies have suggested phosphodiesterase 4 (PDE4) inhibition may be associated with weight loss and other cardiometabolic benefits. We evaluated the effect of the PDE4 inhibitor apremilast on body weight and composition, glucose homeostasis, lipid profiles and vascular function in psoriatic disease and whether weight change correlated with therapeutic response. Methods We conducted a prospective, open-label study (Immune Metabolic Associations in Psoriatic Arthritis) of adults receiving apremilast 30 mg as part of routine care for PsA and/or psoriasis. Cardiometabolic, anthropometric and disease activity assessments were performed at baseline (pre-apremilast) and at months 1, 3 and 6 of apremilast treatment in 60 patients. A subgroup underwent further assessment of endothelial function, body composition and adipocyte morphology. Results In patients (median age 54.5 years, 63% women, median BMI 33.2 kg/m2), apremilast was associated with a mean weight loss of 2.2 kg (95% CI 1.4, 3.0; P Conclusion Following apremilast treatment, we observed weight loss, principally abdominal subcutaneous fat, and improvement in psoriatic disease activity. The latter was independent of weight change, suggesting apremilast likely acts through direct immunological mechanisms.
- Published
- 2021